Clinical trial
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
NCT03337087 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
- Lead sponsor
- Academic and Community Cancer Research United
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 2, 2018
- Completion date
- August 9, 2025
- Enrollment
- 18 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic biliary tract carcinoma, metastatic colorectal carcinoma, metastatic gastroesophageal junction adenocarcinoma, metastatic malignant digestive system neoplasm, metastatic pancreatic adenocarcinoma, stage iv colorectal cancer ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, stage iva colorectal cancer ajcc v7, stage ivb colorectal cancer ajcc v7